凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2014年第一季度报告全文

公告日期 2014-04-26
股票简称:莱茵生物 股票代码:002166
                  桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




桂林莱茵生物科技股份有限公司

     2014 年第一季度报告




        2014 年 04 月




              1
                                      桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人姚新德、主管会计工作负责人周庆伟及会计机构负责人(会计主

管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                  2
                                                              桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




                            第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                                                                               本报告期比上年同期增减
                                             本报告期                    上年同期
                                                                                                       (%)

营业收入(元)                                   67,033,533.56               95,142,400.97                     -29.54%

归属于上市公司股东的净利润(元)                  1,077,765.89                1,805,506.51                     -40.31%

归属于上市公司股东的扣除非经常性损
                                                    857,884.19                1,334,999.12                     -35.74%
益的净利润(元)

经营活动产生的现金流量净额(元)                 69,223,442.35              -89,476,868.08                     177.36%

基本每股收益(元/股)                                         0.01                      0.01                       0%

稀释每股收益(元/股)                                         0.01                      0.01                       0%

加权平均净资产收益率(%)                                 0.55%                         1.1%                    -0.55%

                                                                                               本报告期末比上年度末增
                                             本报告期末                  上年度末
                                                                                                       减(%)

总资产(元)                                   1,125,229,600.31           1,149,099,935.23                      -2.08%

归属于上市公司股东的净资产(元)                198,404,491.78              197,199,526.77                      0.61%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                               单位:元

                         项目                                 年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                     -34,151.63

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                            33,800.00
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                                 219,733.33

除上述各项之外的其他营业外收入和支出                                           500.00

合计                                                                       219,881.70                  --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用




                                                          3
                                                         桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


二、报告期末股东总数及前十名股东持股情况表

                                                                                                          单位:股

报告期末股东总数                                                                                           41,460

                                            前 10 名股东持股情况

                                                                 持有有限售条件          质押或冻结情况
   股东名称         股东性质    持股比例(%)    持股数量
                                                                   的股份数量        股份状态          数量

秦本军           境内自然人            19.77%       25,613,504                    质押                 25,613,504

姚新德           境内自然人             8.71%       11,286,403        10,201,207 质押                  11,286,403

蒋安明           境内自然人             2.39%        3,101,576

中融国际信托有
限公司-国鑫九
                 其他                   0.47%         610,000
号证券投资集合
资金信托计划

陈巧云           境内自然人             0.38%         495,979

厦门国际信托有
限公司-绿河二    其他                   0.36%         461,806
号集合资金信托

黎科弟           境内自然人             0.34%         434,067

赵条姑           境内自然人             0.27%         355,799

刘蕊             境内自然人             0.27%         350,000

伍立文           境内自然人             0.26%         337,701

                                       前 10 名无限售条件股东持股情况

                                                                                            股份种类
           股东名称                       持有无限售条件股份数量
                                                                                     股份种类          数量

秦本军                                                                25,613,504 人民币普通股          25,613,504

蒋安明                                                                 3,101,576 人民币普通股           3,101,576

姚新德                                                                 1,085,196 人民币普通股           1,085,196

中融国际信托有限公司-国鑫九
                                                                        610,000 人民币普通股              610,000
号证券投资集合资金信托计划

陈巧云                                                                  495,979 人民币普通股              495,979

厦门国际信托有限公司-绿河二号
                                                                        461,806 人民币普通股              461,806
集合资金信托

黎科弟                                                                  434,067 人民币普通股              434,067

赵条姑                                                                  355,799 人民币普通股              355,799

刘蕊                                                                    350,000 人民币普通股              350,000



                                                     4
                                                         桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


伍立文                                                                337,701 人民币普通股           337,701

上述股东关联关系或一致行动的   公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关联关系以外,
说明                           公司前 3 大股东之间不存在关联关系或一致行动,其他股东之间关系不详。

公司股东在报告期内是否进行约定购回交易
□ 是 √ 否




                                                     5
                                                            桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




                                        第三节 重要事项

一、报告期主要会计报表项目、财务指标发生重大变动的情况及原因

                                                                                                         单位:元
       项目           期末数/             期初数/           变动幅度                      说明
                     本期发生数        上年同期发生数
货币资金               13,899,897.45      38,680,937.10       -64.07% 主要系报告期偿还银行贷款增加所致。
应收票据                                     100,000.00      -100.00% 系报告期应收票据已贴现所致。
在建工程                 249,417.00          188,037.00       32.64% 系报告期新工厂前期筹建费用增加所致。
短期借款               20,515,259.70     106,507,253.68       -80.74% 系报告期归还银行贷款增加所致。
应付账款               70,073,229.15     111,795,931.20       -37.32% 系报告期支付供应商货款增加所致。
                                                                        主要系报告期莱茵投资收到BT项目回购资金所
预收款项              120,909,972.27         578,487.70 20801.04%
                                                                        致。
应付职工薪酬             524,086.53        3,461,412.20       -84.86% 系报告期支付上年度绩效工资所致。
其他应付款              4,972,059.71      17,599,108.13       -71.75% 主要系报告期归还暂借款所致。
营业收入               67,033,533.56      95,142,400.97       -29.54% 系报告期BT项目营业收入减少所致。
营业成本               50,995,414.93      75,091,629.37       -32.09% 系报告期营业收入减少相应营业成本减少所致。
                                                                        系报告期营业收入减少相应营业税金及附加减
营业税金及附加           157,799.80        1,817,798.35       -91.32%
                                                                        少所致。
财务费用                5,992,390.50       8,686,512.58       -31.02% 系报告期银行贷款减少所致。
投资收益                 387,586.05          251,335.13       54.21% 系报告期收到现金分红增加所致。
营业外收入                 35,300.00         533,626.39       -93.38% 系报告期取得政府补助减少所致。
                                                                        主要系BT项目上年同期因项目施工造成树木损
营业外支出                 35,151.63         201,119.00       -82.52%
                                                                        害而产生的赔款导致营业外支出增加。
经营活动产生的现金                                                      主要系报告期植物提取业务销售回款增加以及
                       69,223,442.35      -89,476,868.08     177.36%
流量净额                                                                收到BT项目回购资金所致。
投资活动产生的现金
                         372,808.05        -2,889,192.20     112.90% 主要系报告期资本性支出减少所致。
流量净额
筹资活动产生的现金
                      -94,401,028.50      95,458,890.99      -198.89% 主要系报告期偿还银行贷款增加所致。
流量净额


二、重要事项进展情况及其影响和解决方案的分析说明

    2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYNUSA
与美国嘉吉股份有限公司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供
应协议》。根据协议的相关约定,该协议已经自动续约2年至2015年11月1日止。本报告期内,公司收到嘉
吉公司订单280.98万美元,执行订单310.75万美元。从协议生效至本报告期末,公司累计已收到嘉吉公司
订单3,104.82万美元,累计已执行订单2,367.19万美元,尚有737.60万美元订单未交付。

                                                        6
                                                                桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




           重要事项概述                              披露日期                             临时报告披露网站查询索引

                                                                                  巨潮资讯网 www.cninfo.com.cn,公告编
BT 项目合同实施进展公告               2014 年 04 月 08 日
                                                                                  号 2014-013。


三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项

                                                                                                         承诺
     承诺事项         承诺方                          承诺内容                                承诺时间          履行情况
                                                                                                         期限

股改承诺

收购报告书或权益变
动报告书中所作承诺

资产重组时所作承诺

                               本公司上市时,当时持有本公司 5%以上股份的股东秦本军、
                               姚新德、杨晓涛及蒋安明向本公司出具了《避免同业竞争承
                     秦本军、 诺函》,承诺:“本人将不在中国境内外直接或间接从事或参                            截至本公
首次公开发行或再融 姚新德、 与任何在商业上对股份公司构成竞争的业务或活动,或拥有 2007 年 09 长期                告披露日,
资时所作承诺         杨晓涛及 与股份公司存在竞争关系的任何经济实体、机构、经济组织 月 13 日              履行   该承诺正
                     蒋安明    的权益,或以其他任何形式取得该经济实体、机构、经济组                             在履行中。
                               织的控制权,或在该经济实体、机构、经济组织中担任高级
                               管理人员或核心技术人员。”

其他对公司中小股东
所作承诺

承诺是否及时履行     是


四、对 2014 年 1-6 月经营业绩的预计

2014 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2014 年 1-6 月归属于上市公司股东的净利润变动幅度(%)                     110%       至                              160%

2014 年 1-6 月归属于上市公司股东的净利润变动区间(万元)                  1,200      至                              1,500

2013 年 1-6 月归属于上市公司股东的净利润(万元)                                                                    568.55

                                                                公司继续加大国际市场维护和开拓力度,植物提取业务保
                                                                持良好的发展态势,BT 项目将确认部分收益,同时,处置
                                                                锦汇投资 20%股权的交易将帮助公司取得投资收益约
业绩变动的原因说明                                              451.19 万元。该盈利预测仅在基于公司目前可预见的经营
                                                                环境变化及工程项目施工验收进度的基础上作出,如果外
                                                                部环境发生一定变化,将会对公司业绩造成较大影响,上
                                                                述业绩预测将存在需要进行调整的风险。




                                                            7
                                                        桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                     单位:元

                 项目                        期末余额                               期初余额

流动资产:

    货币资金                                             13,899,897.45                          38,680,937.10

    结算备付金

    拆出资金

    交易性金融资产

    应收票据                                                                                      100,000.00

    应收账款                                             72,553,610.75                          76,936,169.74

    预付款项                                              5,873,649.08                           6,092,676.36

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                              8,432,540.36                           8,212,807.03

    应收股利

    其他应收款                                           84,650,873.69                          95,486,290.25

    买入返售金融资产

    存货                                                465,977,453.62                         448,073,073.83

    一年内到期的非流动资产

    其他流动资产                                          4,987,844.66                           5,474,230.58

流动资产合计                                            656,375,869.61                         679,056,184.89

非流动资产:

    发放委托贷款及垫款

    可供出售金融资产

    持有至到期投资

    长期应收款                                           14,500,000.00                          11,500,000.00

    长期股权投资                                         39,593,640.00                          39,593,640.00



                                                  8
                             桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


    投资性房地产              266,578,591.21                       267,671,113.39

    固定资产                  142,133,938.78                       145,130,202.48

    在建工程                      249,417.00                          188,037.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                      978,190.25                         1,030,422.71

    开发支出

    商誉

    长期待摊费用                1,103,813.00                         1,214,194.30

    递延所得税资产              3,716,140.46                         3,716,140.46

    其他非流动资产

非流动资产合计                468,853,730.70                       470,043,750.34

资产总计                     1,125,229,600.31                    1,149,099,935.23

流动负债:

    短期借款                   20,515,259.70                       106,507,253.68

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    交易性金融负债

    应付票据

    应付账款                   70,073,229.15                       111,795,931.20

    预收款项                  120,909,972.27                          578,487.70

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                  524,086.53                         3,461,412.20

    应交税费                    7,808,785.84                         8,985,852.66

    应付利息                    1,006,886.22                         1,342,841.60

    应付股利

    其他应付款                  4,972,059.71                        17,599,108.13

    应付分保账款

    保险合同准备金

    代理买卖证券款



                         9
                                                             桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


     代理承销证券款

     一年内到期的非流动负债                                   211,720,397.04                         212,145,887.43

     其他流动负债                                               5,991,417.28                           6,776,523.88

流动负债合计                                                  443,522,093.74                         469,193,298.48

非流动负债:

     长期借款                                                 285,000,000.00                         285,000,000.00

     应付债券

     长期应付款

     专项应付款                                               179,909,426.92                         179,909,426.92

     预计负债

     递延所得税负债                                             2,053,201.75                           2,053,201.75

     其他非流动负债                                            16,168,483.00                          15,568,483.00

非流动负债合计                                                483,131,111.67                         482,531,111.67

负债合计                                                      926,653,205.41                         951,724,410.15

所有者权益(或股东权益):

     实收资本(或股本)                                       129,533,760.00                         129,533,760.00

     资本公积                                                  83,217,530.86                          83,217,530.86

     减:库存股

     专项储备

     盈余公积                                                   8,834,943.24                           8,834,943.24

     一般风险准备

     未分配利润                                                -22,626,567.32                         -23,704,333.21

     外币报表折算差额                                            -555,175.00                            -682,374.12

归属于母公司所有者权益合计                                    198,404,491.78                         197,199,526.77

     少数股东权益                                                 171,903.12                             175,998.31

所有者权益(或股东权益)合计                                  198,576,394.90                         197,375,525.08

负债和所有者权益(或股东权益)总
                                                             1,125,229,600.31                       1,149,099,935.23



法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


2、母公司资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                            单位:元

                  项目                            期末余额                               期初余额


                                                       10
                                  桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


流动资产:

    货币资金                        8,807,016.54                         36,159,744.42

    交易性金融资产

    应收票据                                                               100,000.00

    应收账款                       54,374,317.86                         58,875,278.18

    预付款项                        2,764,288.63                          3,005,500.75

    应收利息

    应收股利

    其他应收款                     29,644,966.36                         26,391,110.16

    存货                          175,729,536.02                        167,411,720.97

    一年内到期的非流动资产

    其他流动资产                    4,549,945.41                          4,891,738.33

流动资产合计                      275,870,070.82                        296,835,092.81

非流动资产:

    可供出售金融资产

    持有至到期投资

    长期应收款

    长期股权投资                  157,051,040.21                        157,051,040.21

    投资性房地产                  266,578,591.21                        267,671,113.39

    固定资产                      133,644,552.73                        136,361,780.64

    在建工程                          249,417.00                           188,037.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                          814,671.05                           862,186.61

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                  3,541,722.06                          3,541,722.06

    其他非流动资产

非流动资产合计                    561,879,994.26                        565,675,879.91

资产总计                          837,750,065.08                        862,510,972.72

流动负债:



                             11
                                        桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


    短期借款                             10,515,259.70                         96,507,253.68

    交易性金融负债

    应付票据

    应付账款                             28,169,604.92                         16,901,579.98

    预收款项                                909,972.27                           578,487.70

    应付职工薪酬                            107,651.50                          2,557,850.20

    应交税费                              1,537,302.34                          2,718,318.46

    应付利息                                 63,060.62                           391,486.63

    应付股利

    其他应付款                          311,201,076.99                        263,937,781.97

    一年内到期的非流动负债               11,576,448.00                         11,576,448.00

    其他流动负债

流动负债合计                            364,080,376.34                        395,169,206.62

非流动负债:

    长期借款                             85,000,000.00                         85,000,000.00

    应付债券

    长期应付款

    专项应付款                          179,909,426.92                        179,909,426.92

    预计负债

    递延所得税负债

    其他非流动负债                       16,168,483.00                         15,568,483.00

非流动负债合计                          281,077,909.92                        280,477,909.92

负债合计                                645,158,286.26                        675,647,116.54

所有者权益(或股东权益):

    实收资本(或股本)                  129,533,760.00                        129,533,760.00

    资本公积                             83,217,530.86                         83,217,530.86

    减:库存股

    专项储备

    盈余公积                              8,834,943.24                          8,834,943.24

    一般风险准备

    未分配利润                           -28,994,455.28                       -34,722,377.92

    外币报表折算差额

所有者权益(或股东权益)合计            192,591,778.82                        186,863,856.18

负债和所有者权益(或股东权益)总        837,750,065.08                        862,510,972.72



                                   12
                                                             桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文





法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


3、合并利润表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                         单位:元

                 项目                             本期金额                               上期金额

一、营业总收入                                                67,033,533.56                         95,142,400.97

       其中:营业收入                                         67,033,533.56                         95,142,400.97

            利息收入

            已赚保费

            手续费及佣金收入

二、营业总成本                                                66,347,597.28                         93,925,475.24

       其中:营业成本                                         50,995,414.93                         75,091,629.37

            利息支出

            手续费及佣金支出

            退保金

            赔付支出净额

            提取保险合同准备金净额

            保单红利支出

            分保费用

            营业税金及附加                                       157,799.80                          1,817,798.35

            销售费用                                           2,105,543.99                          2,700,620.03

            管理费用                                           7,096,448.06                          5,629,164.91

            财务费用                                           5,992,390.50                          8,686,512.58

            资产减值损失                                                                                  -250.00

       加:公允价值变动收益(损失以
“-”号填列)

            投资收益(损失以“-”号
                                                                 387,586.05                           251,335.13
填列)

            其中:对联营企业和合营
企业的投资收益

            汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)                             1,073,522.33                          1,468,260.86


                                                       13
                                                               桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


       加:营业外收入                                               35,300.00                           533,626.39

       减:营业外支出                                               35,151.63                           201,119.00

            其中:非流动资产处置损
                                                                    34,151.63


四、利润总额(亏损总额以“-”号填
                                                                 1,073,670.70                          1,800,768.25
列)

       减:所得税费用

五、净利润(净亏损以“-”号填列)                               1,073,670.70                          1,800,768.25

       其中:被合并方在合并前实现的
净利润

       归属于母公司所有者的净利润                                1,077,765.89                          1,805,506.51

       少数股东损益                                                 -4,095.19                             -4,738.26

六、每股收益:                                       --                                       --

       (一)基本每股收益                                                0.01                                  0.01

       (二)稀释每股收益                                                0.01                                  0.01

七、其他综合收益                                                   127,199.12                           -318,530.77

八、综合收益总额                                                 1,200,869.82                          1,482,237.48

       归属于母公司所有者的综合收益
                                                                 1,204,965.01                          1,486,975.74
总额

       归属于少数股东的综合收益总额                                 -4,095.19                             -4,738.26


法定代表人:姚新德                       主管会计工作负责人:周庆伟                        会计机构负责人:张为鹏


4、母公司利润表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                           单位:元

                 项目                             本期金额                                 上期金额

一、营业收入                                                    59,838,933.73                         38,168,283.96

       减:营业成本                                             45,298,340.81                         25,808,543.35

           营业税金及附加                                               27.56                           141,227.82

           销售费用                                              1,365,637.81                          1,343,305.26

           管理费用                                              5,872,017.03                          4,267,331.14

           财务费用                                              1,962,222.30                          5,723,219.53

           资产减值损失

       加:公允价值变动收益(损失以
“-”号填列)


                                                          14
                                                               桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


           投资收益(损失以“-”号填
                                                                   387,586.05                           251,335.13
列)

           其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)                               5,728,274.27                          1,135,991.99

       加:营业外收入                                               33,800.00                           533,626.39

       减:营业外支出                                               34,151.63                              1,119.00

           其中:非流动资产处置损失                                 34,151.63                              1,119.00

三、利润总额(亏损总额以“-”号填
                                                                 5,727,922.64                          1,668,499.38
列)

       减:所得税费用

四、净利润(净亏损以“-”号填列)                               5,727,922.64                          1,668,499.38

五、每股收益:                                       --                                       --

       (一)基本每股收益                                                0.04                                  0.01

       (二)稀释每股收益                                                0.04                                  0.01

六、其他综合收益

七、综合收益总额                                                 5,727,922.64                          1,668,499.38


法定代表人:姚新德                       主管会计工作负责人:周庆伟                        会计机构负责人:张为鹏


5、合并现金流量表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                           单位:元

                 项目                             本期金额                                 上期金额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                            191,110,793.37                         66,672,028.23

       客户存款和同业存放款项净增加


       向中央银行借款净增加额

       向其他金融机构拆入资金净增加


       收到原保险合同保费取得的现金

       收到再保险业务现金净额

       保户储金及投资款净增加额

       处置交易性金融资产净增加额

       收取利息、手续费及佣金的现金


                                                          15
                                         桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                        2,179,748.87                          1,633,703.12

     收到其他与经营活动有关的现金            273,036.42                        204,202,436.07

经营活动现金流入小计                     193,563,578.66                        272,508,167.42

     购买商品、接受劳务支付的现金         99,283,117.67                        341,774,715.18

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                          11,916,982.46                          8,150,561.47


     支付的各项税费                        2,259,720.55                          1,403,648.49

     支付其他与经营活动有关的现金         10,880,315.63                         10,656,110.36

经营活动现金流出小计                     124,340,136.31                        361,985,035.50

经营活动产生的现金流量净额                69,223,442.35                        -89,476,868.08

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益所收到的现金                387,586.05                           251,335.13

     处置固定资产、无形资产和其他
                                              35,500.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金            600,000.00

投资活动现金流入小计                       1,023,086.05                           251,335.13

     购建固定资产、无形资产和其他
                                             650,278.00                          3,140,527.33
长期资产支付的现金

     投资支付的现金

     质押贷款净增加额

     取得子公司及其他营业单位支付
的现金净额

     支付其他与投资活动有关的现金

投资活动现金流出小计                         650,278.00                          3,140,527.33

投资活动产生的现金流量净额                   372,808.05                         -2,889,192.20


                                    16
                                                             桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


三、筹资活动产生的现金流量:

       吸收投资收到的现金

       其中:子公司吸收少数股东投资
收到的现金

       取得借款收到的现金                                     16,636,890.00                         122,920,862.92

       发行债券收到的现金

       收到其他与筹资活动有关的现金                           35,604,800.00                         100,000,000.00

筹资活动现金流入小计                                          52,241,690.00                         222,920,862.92

       偿还债务支付的现金                                    102,867,765.17                          11,287,100.00

       分配股利、利润或偿付利息支付
                                                               9,487,996.66                          12,123,791.59
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现金                           34,286,956.67                         104,051,080.34

筹资活动现金流出小计                                         146,642,718.50                         127,461,971.93

筹资活动产生的现金流量净额                                    -94,401,028.50                         95,458,890.99

四、汇率变动对现金及现金等价物的
                                                                  23,738.45                            -372,753.42
影响

五、现金及现金等价物净增加额                                  -24,781,039.65                          2,720,077.29

       加:期初现金及现金等价物余额                           38,680,937.10                          41,151,733.01

六、期末现金及现金等价物余额                                  13,899,897.45                          43,871,810.30


法定代表人:姚新德                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


6、母公司现金流量表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元

                 项目                             本期金额                               上期金额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                           68,570,076.74                          61,632,008.44

       收到的税费返还                                          2,179,748.87                           1,633,703.12

       收到其他与经营活动有关的现金                               58,924.87                         204,130,423.94

经营活动现金流入小计                                          70,808,750.48                         267,396,135.50

       购买商品、接受劳务支付的现金                           40,095,045.57                         295,661,621.83

       支付给职工以及为职工支付的现
                                                               9,482,678.20                           5,840,762.19



                                                       17
                                           桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


       支付的各项税费                        1,249,445.21                          1,389,403.52

       支付其他与经营活动有关的现金          6,174,177.79                          6,352,248.36

经营活动现金流出小计                        57,001,346.77                        309,244,035.90

经营活动产生的现金流量净额                  13,807,403.71                        -41,847,900.40

二、投资活动产生的现金流量:

       收回投资收到的现金

       取得投资收益所收到的现金                387,586.05                           251,335.13

       处置固定资产、无形资产和其他
                                                35,500.00
长期资产收回的现金净额

       处置子公司及其他营业单位收到
的现金净额

       收到其他与投资活动有关的现金            600,000.00

投资活动现金流入小计                         1,023,086.05                           251,335.13

       购建固定资产、无形资产和其他
                                               650,278.00                          1,224,450.00
长期资产支付的现金

       投资支付的现金

       取得子公司及其他营业单位支付
的现金净额

       支付其他与投资活动有关的现金

投资活动现金流出小计                           650,278.00                          1,224,450.00

投资活动产生的现金流量净额                     372,808.05                           -973,114.87

三、筹资活动产生的现金流量:

       吸收投资收到的现金

       取得借款收到的现金                   16,636,890.00                          7,920,862.92

       发行债券收到的现金

       收到其他与筹资活动有关的现金         72,000,000.00                        179,000,000.00

筹资活动现金流入小计                        88,636,890.00                        186,920,862.92

       偿还债务支付的现金                  102,867,765.17                         11,287,100.00

       分配股利、利润或偿付利息支付
                                             2,315,467.30                          8,309,624.93
的现金

       支付其他与筹资活动有关的现金         25,000,000.00                        106,000,000.00

筹资活动现金流出小计                       130,183,232.47                        125,596,724.93

筹资活动产生的现金流量净额                  -41,546,342.47                        61,324,137.99

四、汇率变动对现金及现金等价物的
                                                13,402.83                           -371,606.44
影响

五、现金及现金等价物净增加额                -27,352,727.88                        18,131,516.28


                                      18
                                                       桂林莱茵生物科技股份有限公司 2014 年第一季度报告全文


     加:期初现金及现金等价物余额                       36,159,744.42                         10,785,342.58

六、期末现金及现金等价物余额                             8,807,016.54                         28,916,858.86


法定代表人:姚新德                  主管会计工作负责人:周庆伟                     会计机构负责人:张为鹏


二、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                                                         桂林莱茵生物科技股份有限公司

                                                                         法定代表人:

                                                                                             姚新德

                                                                                二〇一四年四月二十四日




                                                  19
数据加载中...
prevnext
手机查看股票